Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis - Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665- 73.
Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 2005;52:1333-4.
Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 2005;52:1333-4.
4
0742306799
Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab
Buda-Okreglak EM, Drabick JJ, Delaney NR. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab. Ann Hematol 2004;83:117-19.
The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: A review
In press
Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008. In press.
New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect?
Roux CH, Brocq O, Leccia N, Giacchero D, Breuil V, Albert C, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol 2007;34:434-7.
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Brit J Dermatol 2007;156:486-91.